Differential regulation of human blood glucose level by interleukin-2 and -6

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 1, 2005, Pages 43-48

  Harnish, M J ^a   Lange, Tanja ^a   Dimitrov, S ^a   Born, J ^a   Fehm, H L ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Acute phase reaction; Counter regulatory hormones; Cytokines; Glucose regulation; Immune system; Inflammation

Indexed keywords

C PEPTIDE; GLUCOSE; HYDROCORTISONE; INTERLEUKIN 2; INTERLEUKIN 6;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; BACTERIAL INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HOST RESISTANCE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REST; VOLUNTEER;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; INTERLEUKIN-6; MALE; OSMOLAR CONCENTRATION; TIME FACTORS;

EID: 14644405653     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830526     Document Type: Article

References (36)

1. Barriere SL, Lowry SF. An overview of mortality risk prediction in sepsis. Crit Care Med 1995; 23: 376-393
2. Battelino T, Goto M, Krzisnik C, Zeller WP. Tumor necrosis factor-alpha alters glucose metabolism in suckling rats. J Lab Clin Med 1999; 133: 583-589
3. Besedovsky HO, del Rey A. Interleukin-1 and glucose homeostasis: An example of the biological relevance of immune-neuroendocrine interactions. Horm Res 1989; 31: 94-99
4. Bierwolf C, Struve K, Marshall L, Born J, Fehm HL. Slow wave sleep drives inhibition of pituitary-adrenal secretion in humans. J Neuroendocrinol 1997; 9: 479-484
5. Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH, Harris R, Hersey P. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br J Cancer 1983; 47: 123-133
6. Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary- induced multisystem organ failure. Ann Thorac Surg 1993; 56: S92-S96
7. Chakrabarti R, Jung CY, Lee TP, Liu H, Mookerjee BK. Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J Immunol l994; 152: 2660-2668
8. Chambrier C, Mercatello A, Tognet E, Cottet-Emard JM, Cohen R, Blay JY, Favrot M, Philip T, Beylot M. Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients. J Biol Response Mod 1990; 9: 251-255
9. Crown J, Jakubowski A, Kemeny N, Gordon M, Gasparetto C, Wong G, Sheridan C, Toner G, Meisenberg B, Botet J. A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78: 1420-1427
10. del Rey A, Besedovsky HO. Interleukin-1 affects glucose homeostasis. Am J Physiol 1987; 253: R794-798
11. del Rey A, Besedovsky HO. Antidiabetic effects of interleukin-1. Proc Natl Acad Sci USA 1989; 86: 5943-5947
12. del Rey A, Monge-Arditi G, Besedovsky HO. Central and peripheral mechanisms contribute to the hypoglycemia induced by interleukin-1. Ann N Y Acad Sci 1998; 840: 153-161
13. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, Scherbaum WA, Vinson GP. Intra-adrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998; 19: 101-143
14. Gesbert F, Delespine-Carmagnat M, Bertoglio J. Recent advances in the understanding of interleukin-2 signal transduction. J Clin Immunol 1998; 18: 307-320
15. Goodman S, Sprung CL. The Int. Sepsis Forum's controversies in sepsis: corticosteroids should be used to treat septic shock. Crit Care 2002; 6: 381-383
16. Hanisch UK, Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res Brain Res Rev 1995; 21: 246-284
17. Lager I: The insulin-antagonistic effect of the counterregulatory hormones. J Intern Med Suppl. 1991; 735: 41-47
18. Lange T, Marshall L, Späth-Schwalbe E, Fehm HL, Born J. Systemic immune parameters and sleep after ultra-low dose administration of IL-2 in healthy men. Brain Behav Immun 2002; 16: 663-674
19. Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 1994; 79: 934-939
20. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17: 107-124
21. Miller SL, Wallace RJ, Musher DM, Septimus EJ, Kohl S, Baughn RE. Hy-poglycemia as a manifestation of sepsis. Am J Med 1980; 68: 649-653
22. Oguri S, Motegi K, Iwakura Y, Endo Y. Primary role of interleukin-1α and interleukin-1β in lipopolysaccharide-induced hypoglycemia in mice. Clin Diag Ub Immunol 2002; 9: 1307-1312
23. Plat L, Leproult R, L'Hermite-Baleriaux M, Fery F, Mockel J, Polonsky KS, Van Cauter E. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab 1999; 84: 3082-3092
24. Petitto JM, Huang Z. Molecular cloning of the coding sequence of an interleukin-2 receptor alpha subunit cDNA in murine brain. J Neuro-immunol 1995; 59: 135-141
25. Ritchie DG. Interleukin 6 stimulates hepatic glucose release from prelabeled glycogen pools. Am J Physiol 1990; 258: E57-E64
26. Ruetten H, Thiemermann C. Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase. Br J Pharmacol 1997; 122: 59-70
27. Sievers EL, Lange BJ, Sondel PM, Krailo MD, Gan J, Liu-Mares W, Feig SA. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: A report from the Children's Cancer Group. J Clin Oncol 1998; 16: 914-919
28. Smith KA. Lowest dose interleukin-2 immunotherapy. Blood 1993; 6: 1414-1424
29. Späth-Schwalbe E, Born J, Schrezenmeier H, Bornstein SR, Stromeyer P, Drechsler S, Fehm HL, Porzsolt F. Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 1994; 79: 1212-1214
30. Späth-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, Fehm HL, Born J. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998; 83: 1573-1579
31. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK. Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 2003; 548: 631-638
32. Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, Sauerwein HP. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 1995; 268: E813-E819
33. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997a; 82: 4167-4170
34. Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 1997b; 66: 54-62
35. Van Cauter E, Polonsky KS, Scheen AJ. Roles of circadian rhythmicity and sleep in human glucose regulation. Endocr Rev 1997; 18: 716-738
36. Witek-Janusek L, Yelich MR. Role of the adrenal cortex and medulla in the young rats' glucoregulatory response to endotoxin. Shock 1995; 3: 434-439